Stellar Capital Management LLC increased its stake in Merck & Co. (NYSE:MRK) by 4.6% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 65,872 shares of the company’s stock after buying an additional 2,900 shares during the quarter. Merck & Co. accounts for approximately 2.5% of Stellar Capital Management LLC’s portfolio, making the stock its 11th largest holding. Stellar Capital Management LLC’s holdings in Merck & Co. were worth $3,707,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the stock. Santori & Peters Inc. purchased a new stake in shares of Merck & Co. in the fourth quarter worth about $110,000. NewSquare Capital LLC lifted its holdings in shares of Merck & Co. by 728.3% in the third quarter. NewSquare Capital LLC now owns 14,801 shares of the company’s stock worth $115,000 after buying an additional 13,014 shares in the last quarter. Stevens First Principles Investment Advisors increased its position in shares of Merck & Co. by 79.3% in the fourth quarter. Stevens First Principles Investment Advisors now owns 2,080 shares of the company’s stock worth $117,000 after purchasing an additional 920 shares during the last quarter. WealthTrust Arizona LLC increased its position in shares of Merck & Co. by 103.7% in the fourth quarter. WealthTrust Arizona LLC now owns 2,495 shares of the company’s stock worth $140,000 after purchasing an additional 1,270 shares during the last quarter. Finally, Taylor Hoffman Wealth Management bought a new position in shares of Merck & Co. in the fourth quarter worth approximately $156,000. 74.87% of the stock is currently owned by institutional investors.
Several research firms recently weighed in on MRK. Deutsche Bank restated a “hold” rating on shares of Merck & Co. in a research report on Wednesday, April 25th. ValuEngine cut shares of Merck & Co. from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. BMO Capital Markets raised their price target on Merck & Co. from $65.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, April 26th. Zacks Investment Research lowered Merck & Co. from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Bank of America raised their price target on Merck & Co. from $68.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, April 17th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $65.87.
NYSE MRK opened at $59.07 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.10 and a current ratio of 1.42. Merck & Co. has a 12 month low of $59.04 and a 12 month high of $59.65. The company has a market capitalization of $161.10 billion, a P/E ratio of 14.84, a price-to-earnings-growth ratio of 2.28 and a beta of 0.76.
Merck & Co. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, May 1st. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.00 by $0.05. The business had revenue of $10.04 billion for the quarter, compared to analysts’ expectations of $10.09 billion. Merck & Co. had a return on equity of 30.93% and a net margin of 4.31%. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.88 EPS. equities analysts forecast that Merck & Co. will post 4.23 earnings per share for the current year.
In other news, insider Weir Mirian M. Graddick sold 24,000 shares of the business’s stock in a transaction that occurred on Monday, April 16th. The stock was sold at an average price of $58.00, for a total transaction of $1,392,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Julie L. Gerberding sold 9,972 shares of the business’s stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $59.66, for a total value of $594,929.52. The disclosure for this sale can be found here. Insiders own 0.32% of the company’s stock.
About Merck & Co.
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.